Patient outcomes following second surgery for recurrent glioblastoma-Reference-Cited by-同舟云学术

Patient outcomes following second surgery for recurrent glioblastoma

Published:2016-04 Issue:8 Volume:12 Page:1039-1044
ISSN:1479-6694
Container-title:Future Oncology
language:en
Short-container-title:Future Oncology

Author:

Brandes Alba A¹,Bartolotti Marco¹,Tosoni Alicia¹,Poggi Rosalba¹,Bartolini Stefania¹,Paccapelo Alexandro¹,Bacci Antonella²,Ghimenton Claudio³,Pession Annalisa⁴,Bortolotti Carlo⁵,Zucchelli Mino⁵,Galzio Renato⁶,Talacchi Andrea⁷,Volpin Lorenzo⁸,Marucci Gianluca⁴,de Biase Dario⁴,Pizzolitto Stefano⁹,Danieli Daniela¹⁰,Ermani Mario¹¹,Franceschi Enrico¹

Affiliation:

1. Department of Medical Oncology, Bellaria Hospital, Azienda USL – IRCCS Institute of Neurological Sciences, Bologna, Italy

2. Department of Neuroradiology, Bellaria Hospital, Azienda USL – IRCCS Institute of Neurological Sciences, Bologna, Italy

3. Department of Pathology, Verona Hospital, Verona, Italy

4. Department of Biomedical & NeuroMotor Sciences (DiBiNeM), University of Bologna, Section of Pathology, M. Malpighi, Bellaria Hospital, Bologna, Italy

5. Department of Neurosurgery, Bellaria Hospital, Azienda USL – IRCCS Institute of Neurological Sciences, Bologna, Italy

6. Department of Health Sciences, University of L’Aquila, L’Aquila, Italy

7. Section of Neurosurgery, Department of Neurological, Neuropsychological, Morphological & Movement Sciences, University of Verona, University Hospital, Verona, Italy

8. Department of Neuroscience & Neurosurgery, San Bortolo Hospital, Vicenza, Italy

9. Department of Pathology, Santa Maria della Misericordia Hospital, Udine, Italy

10. Department of Pathology, San Bortolo Hospital, Vicenza, Italy

11. Department of Neurosciences, Statistic & Informatic Unit, Azienda Ospedale-Università, Padova, Italy

Abstract

Background: The most appropriate management of recurrent glioblastoma is still controversial. In particular, the role of surgery at recurrence remains uncertain. Patients & methods: From our Institutional data warehouse we analyzed 270 consecutive patients who received second surgery for recurrent glioblastoma, to assess survival after second surgery, and to evaluate prognostic factors. Results: Complete resection was found in 128 (47.4%) and partial resection in 142 patients (52.6%). Median survival from second surgery was 11.4 months (95% CI: 10.0–12.7). Multivariate analysis showed that age (p = 0.001), MGMT methylation (p = 0.021) and extent of surgery (p < 0.001) are associated with better survival. Conclusion: A complete resection should be the goal for second resection and younger age and MGMT methylation status might be considered in the selection of patients.

Publisher

Future Medicine Ltd

Subject

Cancer Research,Oncology,General Medicine

Link

https://www.futuremedicine.com/doi/pdf/10.2217/fon.16.9

Reference26 articles.

1. Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma

2. Epidemiology of glial and non-glial brain tumours in Europe

3. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

4. The role of cytoreductive surgery in the management of progressive glioblastoma

5. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands.

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Surgical Management and Advances in the Treatment of Glioma;Seminars in Neurology;2023-11-14

2. Systemic Treatment in Glioblastoma;Glioblastoma - Current Evidence;2023-03-29

3. Updates in the Management of Recurrent Glioblastoma Multiforme;Journal of Neurological Surgery Part A: Central European Neurosurgery;2022-06-30

4. The relationship among integrin alpha 7, CD133 and Nestin as well as their correlation with clinicopathological features and prognosis in astrocytoma patients;Clinical Neurology and Neurosurgery;2022-06

5. Congress of neurological surgeons systematic review and evidence-based guidelines update on the role of cytoreductive surgery in the management of progressive glioblastoma in adults;Journal of Neuro-Oncology;2022-03-04